AARTIPHARM vs HIKAL: Stock Comparison
AARTI PHARMALABS is the larger company by market capitalisation. AARTI PHARMALABS shows a higher ROE, a higher dividend yield and lower leverage, while HIKAL shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AARTIPHARM leads 9; HIKAL leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Live Price | ₹858.8 | ₹222.3 |
| Day Change | -1.07% | -7.51% |
| Volume | 4.63 L | 53.59 L |
| 52-Week High | ₹946.1 | ₹282.7 |
| 52-Week Low | ₹585 | ₹146.25 |
| Distance from 52W High | -9.23% | -21.37% |
Valuation
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Market Cap | ₹7,812 Cr | ₹2,740 Cr |
| P/E Ratio | 36.83x | 0x |
| P/B Ratio | 3.71x | 2.07x |
| EPS | ₹8.4 | ₹-0.6 |
| Book Value | ₹234.3 | ₹97.23 |
| Dividend Yield | 0.46% | 0.09% |
Growth
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Revenue Growth (TTM YoY) | 3.3% | 37.3% |
| EPS Growth (TTM YoY) | -30.8% | 68.3% |
| Qtr Sales Growth | 0.23% | 0% |
| Qtr Profit Growth | 6.78% | 1.33% |
Profitability & Leverage
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| ROE | 9.48% | -4.07% |
| ROCE | 8.38% | -0.87% |
| Net Margin | 10.25% | -2.88% |
| Operating Margin | 16.52% | -0.95% |
| Debt to Equity | 0.35x | 0.57x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Promoter Holding | 42.69%▼ 0.22 pp | 68.85% |
| FII Holding | 8.17%▼ 0.22 pp | 0.99%▼ 0.44 pp |
| DII Holding | 7.22%▼ 0.19 pp | 7.24%▲ 0.04 pp |
| Public Holding | 41.74%▲ 0.63 pp | 22.93%▲ 0.41 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI PHARMALABS and HIKAL.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.